Pulmonary function parameters and use of bronchodilators in patients with cystic fibrosis;Características funcionais pulmonares e uso de broncodilatador em pacientes com fibrose cística

Jornal Brasileiro de Pneumologia

Volumn 39, Issue 1, 2013, Pages 48-55

  Muramatu, Lucia Harumi ^a   Stirbulov, Roberto ^a   Forte, Wilma Carvalho Neves ^b  

^a IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

Author keywords

Bronchodilator agents; Cystic fibrosis; Respiratory function tests

Indexed keywords

BRONCHODILATING AGENT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHILD; CYSTIC FIBROSIS; DRUG EFFECT; FEMALE; HUMAN; LUNG VENTILATION; MALE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADOLESCENT; ANALYSIS OF VARIANCE; BRONCHODILATOR AGENTS; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; PULMONARY VENTILATION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875161268     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37132013000100007     Document Type: Article

References (29)

1. Sturgess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol. 1982;106(3):303-11. PMid:7065115 PMCid:1916229.
2. Ruzal-Shapiro C. Cystic fibrosis. An overview. Radiol Clin North Am. 1998;36(1):143-61. http://dx.doi.org/10.1016/S0033-8389(05)70011-7
3. Rowe SM, Clancy JP. Advances in cystic fibrosis therapies. Curr Opin Pediatr. 2006;18(6):604-13. PMid:17099358. http://dx.doi.org/10.1097/MOP.0b013e3280109b90
4. Flume PA. A role for aerosolized antibiotics. Pediatr Pulmonol. 2008;43(Suppl9):S29-S34. http://dx.doi.org/10.1002/ppul.20859
5. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2005;(4):CD003428. PMid:16235319.
6. Gangell CL, Hall GL, Stick SM, Sly PD; AREST CF. Lung function testing in preschool-aged children with cystic fibrosis in the clinical setting. Pediatr Pulmonol. 2010;45(5):419-33. PMid:20425849.
7. Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes para testes de função pulmonar. JPneumol. 2002;28(Suppl3):S1-S238.
8. Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes da Sociedade Brasileira de Pneumologia e Tisiologia para o manejo da asma-2012. J Bras Pneumol. 2012;38(Suppl1):S1-S46.
9. Polgar G, Promadhat V, editors. Pulmonary function testing in children: techniques and standards. Philadelphia: WB Saunders; 1971. p. 273.
10. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol. 1999;28(4):231-41. http://dx.doi.org/10.1002/(SICI)1099-0496(199910)28:4<231::AID-PPUL1>3.0.CO;2-2
11. Andrade EF, Fonseca DL, Silva FA, Menna-Barreto SS. Avaliação evolutiva da espirometria na fibrose cística. J Pneumol. 2001;27(3):130-6. http://dx.doi.org/10.1590/S0102-35862001000300002
12. Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros. 2010;9(4):250-6. PMid:20471331. http://dx.doi.org/10.1016/j.jcf.2010.04.002
13. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2005;(4):CD003428. PMid:16235319.
14. Konstan MW, VanDevanter DR, Rasouliyan L, Pasta DJ, Yegin A, Morgan WJ, et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol. 2010;45(12):1167-72. PMid:20717935. http://dx.doi.org/10.1002/ppul.21315
15. Cropp GJ. Effectiveness of bronchodilators in cystic fibrosis. Am J Med. 1996;100(1A):19S-29S. http://dx.doi.org/10.1016/S0002-9343(96)80049-0
16. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol. 2002;34(4):287-96. PMid:12205570. http://dx.doi.org/10.1002/ppul.10162
17. Colombo JL. Long-acting bronchodilators in cystic fibrosis. Curr Opin Pulm Med. 2003;9(6):504-8. PMid:14534403. http://dx.doi.org/10.1097/00063198-200311000-00010
18. Zach MS, Oberwaldner B, Forche G, Polgar G. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis. 1985;131(4):537-43. PMid:3994149.
19. Eggleston PA, Rosenstein BJ, Stackhouse CM, Alexander MF. Airway hyperreactivity in cystic fibrosis. Clinical correlates and possible effects on the course of the disease. Chest. 1988;94(2):360-5. PMid:3293930. http://dx.doi.org/10.1378/chest.94.2.360
20. Balfour-Lynn IM. Asthma in cystic fibrosis. J R Soc Med. 2003;96 Suppl43:30-4. PMid:12906323 PMCid:1308785.
21. Forte WC. Hipersinsibilidade tipo I. Rinoconjutivite alérgica, asma brônquica, dermatite atópica, urticária/angiodema, alergia alimentar e reações ao látex. In: Forte WC, editor. Imunologia do básico ao aplicado. São Paulo: Artmed; 2007. p. 179-238.
22. Antunes J, Fernandes A, Borrego LM, Leiria-Pinto P, Cavaco J. Cystic fibrosis, atopy, asthma and ABPA. Allergol Immunopathol (Madr). 2010;38(5):278-84. PMid:20675033. http://dx.doi.org/10.1016/j.aller.2010.06.002
23. Pattishall EN. Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis. Pediatr Pulmonol. 1990;9(2):80-5. PMid:2399051. http://dx.doi.org/10.1002/ppul.1950090204
24. Brand PL. Bronchodilators in cystic fibrosis. J R Soc Med. 2000;93 Suppl38:37-9. PMid:10911817 PMCid:1305882.
25. Salvatore D, D'Andria M. Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatr Pulmonol. 2002;34(1):11-5. PMid:12112791. http://dx.doi.org/10.1002/ppul.10117
26. Nielsen KG, Pressler T, Klug B, Koch C, Bisgaard H. Serial lung function and responsiveness in cystic fibrosis during early childhood. Am J Respir Crit Care Med. 2004;169(11):1209-16. PMid:15028557. http://dx.doi.org/10.1164/rccm.200303-347OC
27. Dodd JD, Barry SC, Daly LE, Gallagher CG. Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. J Cyst Fibros. 2005;4(2):101-5. PMid:15978535. http://dx.doi.org/10.1016/j.jcf.2004.11.004
28. Serisier DJ, Coates AD, Bowler SD. Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest. 2007;131(4):1181-7. PMid:17426226. http://dx.doi.org/10.1378/chest.06-1697
29. Heijerman H, Westerman E, Conway S, Touw D, Döring G; consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros. 2009;8(5):295-315. PMid:19559658. http://dx.doi.org/10.1016/j.jcf.2009.04.005